Lecalpin

Lercanidipine Hydrochloride, the active ingredient in Lecalpin, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Lecalpin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecalpin (Lercanidipine Hydrochloride) belongs to the calcium‑channel blocker class and is used to manage high‑blood‑pressure disorders.

Hypertension: reduces systemic vascular resistance, leading to a sustained decrease in blood pressure.

Lecalpin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness, usually occurring shortly after dosing. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially when standing. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of face, lips, or throat that may compromise airway.

Before initiating therapy with Lecalpin, clinicians should consider several safety aspects.

Monitor blood pressure regularly: ensure therapeutic effect and avoid excessive hypotension. Use caution in hepatic impairment: dose adjustment may be required. Avoid abrupt discontinuation: tapering can reduce rebound hypertension. Exercise caution in elderly patients: increased sensitivity to vasodilatory effects. Contraindicated in known hypersensitivity to lercanidipine or other dihydropyridine calcium‑channel blockers. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lecalpin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Concomitant use with other antihypertensives that cause vasodilation: risk of additive hypotension. - Grapefruit juice: can raise drug levels and precipitate adverse effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem): may enhance cardiac effects. - Diuretics: may potentiate blood‑pressure lowering, requiring dose adjustments.